655 related articles for article (PubMed ID: 20423748)
1. Plasma metabolomic profile in nonalcoholic fatty liver disease.
Kalhan SC; Guo L; Edmison J; Dasarathy S; McCullough AJ; Hanson RW; Milburn M
Metabolism; 2011 Mar; 60(3):404-13. PubMed ID: 20423748
[TBL] [Abstract][Full Text] [Related]
2. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
3. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
[TBL] [Abstract][Full Text] [Related]
4. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
[TBL] [Abstract][Full Text] [Related]
6. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
Ferslew BC; Xie G; Johnston CK; Su M; Stewart PW; Jia W; Brouwer KL; Barritt AS
Dig Dis Sci; 2015 Nov; 60(11):3318-28. PubMed ID: 26138654
[TBL] [Abstract][Full Text] [Related]
7. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
[TBL] [Abstract][Full Text] [Related]
8. A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease.
Chang Y; Gao XQ; Shen N; He J; Fan X; Chen K; Lin XH; Li HM; Tian FS; Li H
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7433-7441. PubMed ID: 32706083
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice.
Tu LN; Showalter MR; Cajka T; Fan S; Pillai VV; Fiehn O; Selvaraj V
Sci Rep; 2017 Jul; 7(1):6120. PubMed ID: 28733574
[TBL] [Abstract][Full Text] [Related]
10. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
[TBL] [Abstract][Full Text] [Related]
11. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
[TBL] [Abstract][Full Text] [Related]
12. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
13. TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice.
Zhao M; Zhao L; Xiong X; He Y; Huang W; Liu Z; Ji L; Pan B; Guo X; Wang L; Cheng S; Xu M; Yang H; Yin Y; Garcia-Barrio MT; Chen YE; Meng X; Zheng L
Gastroenterology; 2020 Jun; 158(8):2266-2281.e27. PubMed ID: 32105727
[TBL] [Abstract][Full Text] [Related]
14. Serum homocysteine levels in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Patsiaoura K; Katsiki E; Zafeiriadou E; Deretzi G; Zavos C; Gavalas E; Katsinelos P; Mane V; Slavakis A
Ann Hepatol; 2012; 11(1):68-76. PubMed ID: 22166563
[TBL] [Abstract][Full Text] [Related]
15. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.
Lake AD; Novak P; Shipkova P; Aranibar N; Robertson DG; Reily MD; Lehman-McKeeman LD; Vaillancourt RR; Cherrington NJ
Amino Acids; 2015 Mar; 47(3):603-15. PubMed ID: 25534430
[TBL] [Abstract][Full Text] [Related]
16. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.
Yang RX; Hu CX; Sun WL; Pan Q; Shen F; Yang Z; Su Q; Xu GW; Fan JG
Sci Rep; 2017 Sep; 7(1):10517. PubMed ID: 28874844
[TBL] [Abstract][Full Text] [Related]
17. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression.
Barr J; Caballería J; Martínez-Arranz I; Domínguez-Díez A; Alonso C; Muntané J; Pérez-Cormenzana M; García-Monzón C; Mayo R; Martín-Duce A; Romero-Gómez M; Lo Iacono O; Tordjman J; Andrade RJ; Pérez-Carreras M; Le Marchand-Brustel Y; Tran A; Fernández-Escalante C; Arévalo E; García-Unzueta M; Clement K; Crespo J; Gual P; Gómez-Fleitas M; Martínez-Chantar ML; Castro A; Lu SC; Vázquez-Chantada M; Mato JM
J Proteome Res; 2012 Apr; 11(4):2521-32. PubMed ID: 22364559
[TBL] [Abstract][Full Text] [Related]
18. Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics approach.
Jin R; McConnell R; Catherine C; Xu S; Walker DI; Stratakis N; Jones DP; Miller GW; Peng C; Conti DV; Vos MB; Chatzi L
Environ Int; 2020 Jan; 134():105220. PubMed ID: 31744629
[TBL] [Abstract][Full Text] [Related]
19. LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity.
Bertran L; Capellades J; Abelló S; Durán-Bertran J; Aguilar C; Martinez S; Sabench F; Correig X; Yanes O; Auguet T; Richart C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372937
[TBL] [Abstract][Full Text] [Related]
20. High Throughput Screening of Serum γ-Glutamyl Dipeptides for Risk Assessment of Nonalcoholic Steatohepatitis with Impaired Glutathione Salvage Pathway.
Saoi M; Sasaki K; Sagawa H; Abe K; Kogiso T; Tokushige K; Hashimoto E; Ohashi Y; Britz-McKibbin P
J Proteome Res; 2020 Jul; 19(7):2689-2699. PubMed ID: 31483669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
